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Objectives: The aim of this study was to assess the clonal structure, virulence potential
and antibiotic susceptibility of uropathogenic Escherichia coli (UPEC) isolates causing
community acquired urinary tract infection (CAUTI) in unselected primary care patients in
Switzerland.
Methods: We performed multilocus sequence typing, virulence factor determination,
and phenotypic and genotypic antimicrobial resistance testing on 44 non-duplicate
UPEC isolates.
Results: Twenty-seven different sequence types (STs) were identified. Major UPEC
clones were represented by 19 (43.2%) of the isolates, including E. coli ST131, ST69
(both 13.6%), ST73 (6.8%), ST10 (4.5%), ST127, ST140, (both 2.3%). Five (11.4%)
isolates belonged to ST141.
Aggregate virulence factor (VF) scores were highest among isolates belonging to ST127
and ST141. Overall, 50% of the isolates were susceptible to all 12 antimicrobials tested,
and all isolates remained susceptible to fosfomycin and nitrofurantoin. Resistance to
sulfamethoxazole and ciprofloxacin were found in 31.8, and 15.9% of the isolates,
respectively. Plasmid-mediated resistance genes were detected in ST69 and ST131
and included aac(6′)-Ib-cr (2.3% of all isolates) blaCTX−M−14 and blaCTX−M−15 (9%), and
mph(A) (13.6%). None of the isolates tested positive for mcr-1 or mcr-2.
Conclusions: Our results show that CAUTI in Switzerland is caused by a wide variety
of UPEC STs for which fosfomycin remains a good treatment option. We suggest that
ST141 is an emerging clone associated with UTI in the community, and warrants closer
attention. Moreover, the high rate of E. coli harboring mph(A) from patients without a
history of antimicrobial therapy or hospitalization indicates that UPEC is an important
reservoir for mph(A).
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INTRODUCTION
Urinary tract infection (UTI) is one of the most common
bacterial infections, frequently affecting young women and
women in the early postmenopausal period (Nicolle, 2013).
UTI represent a major public health burden worldwide (Marrs
et al., 2005; Totsika et al., 2012). Escherichia coli is the single
most important causative agent of UTI, accounting for 75–
85% of the episodes (Foxman, 2010). Although E. coli occurs
naturally in the digestive tract of humans and animals as a
commensal non-pathogenic, two subdivisions of this species
constitute, by virtue of their possession of virulence factors (VF),
etiological agents of either intestinal infections or extraintestinal
diseases (Nataro and Kaper, 1998). Extraintestinal pathogenic E.
coli (ExPEC) include uropathogenic E. coli (UPEC), newborn
meningitis E. coli (NMEC), and avian pathogenic E. coli (APEC)
which causes respiratory tract infections and septicemia in
poultry (Kaper et al., 2004). Many UPEC strains belong to a
limited number of clonal groups exhibiting specific genotypes,
a range of virulence characteristics and varying patterns of
resistance to antimicrobials (Gibreel et al., 2012). Pandemic
UPEC clones include sequence type (ST)131, ST69, ST73, and
ST95 (Tartof et al., 2005; Totsika et al., 2012; Banerjee et al.,
2013a; Doumith et al., 2015). Other lineages such as ST10
and ST127 represent more recently emerged UPEC clones
(Gibreel et al., 2012; Olesen et al., 2012; Alghoribi et al.,
2014). A plethora of VF genes encoding adhesins, toxins,
siderophores, capsules, and other factors have been associated
with UPEC but to date, no specific set of virulence factors
exist for defining an E. coli as uropathogenic (Flores-Mireles
et al., 2015; Singer, 2015). Globally successful, highly virulent
UPEC lineages are recognized for their potential to acquire
and disseminate antimicrobial resistance genes, for example the
extended-spectrum ß-lactamase (ESBL)-producing E. coli ST131
or the trimethoprim-sulfamethoxazole resistant E. coli Clonal
Group A (CGA), a clone that clusters within ST69 (Woodford
et al., 2011; Riley, 2014). Antimicrobial resistance affects every
level of health care, including primary care (Goossens et al., 2005;
European Centre for Disease Prevention and Control, European
Food Safety Authority, and European Medicines Agency, 2017).
However, information of the prevalence of resistance among
E. coli causing community-acquired urinary tract infections
(CAUTI) is rare. Treatment for uncomplicated CAUTI is for
the most part empirical and does not include obtaining a
urine specimen for culture. Diagnostic laboratory-based data on
resistant UPEC thus represent a subset of E. coli causing CAUTI
and furthermore do not includemolecular characterization of the
isolates. The UPEC strains analyzed in this study are particular
in that they originate from a primary health care setting where
microbiological diagnostics are in most cases not required or
recommended (Gupta et al., 2011). Hence, any potential bias
toward over-representation of complicated clinical situations
that laboratory-based strain collections may present is avoided.
The aim of this study was to evaluate the clonal distribution,
virulence markers and resistance patterns of UPEC collected
from patients consulting a general practitioner with symptoms
of UTI.
MATERIALS AND METHODS
Specimen and Clinical Data Collection
Urine samples were collected between February 2016 and
June 2016 from a total of 96 patients presenting to their
general practitioner with symptoms of UTI. The practice for
general medicine is situated in a suburban community in
the region of Zürich, Switzerland and has a catchment area
of 10,000 people of all age groups, levels of education and
professions. The patient collective is therefore representative
for the average Swiss primary care patient. Informed consent
was obtained from the participating patients and the study was
approved by the local ethics committee of Zürich (BASEC-
Nr.Req-2016-00374). Medical records were reviewed to obtain
demographic and clinical data. Comorbidities were defined as
one or more coexisting medical conditions that were additional
to the diagnosis of UTI. Dipstick urinalysis was performed
using Combur R© urine test sticks (Roche, Rotkreuz, Switzerland).
Specimens giving an elevated white cell count were collected
using sterile screw-cap collection tubes containing boric acid,
sodium formate and sodium borate as a preservative (Becton
Dickinson, Allschwil, Switzerland). Thereafter, samples were
diluted 1:1,000 in sterile 0.9% NaCl and 100 µl were streaked
on UTI Brilliance agar (Oxoid, Pratteln, Switzerland) and on
MacConkey agar (Becton Dickinson, Allschwil, Switzerland)
used as growth controls. From plates corresponding to
samples with a viable cell count of ≥104 colony forming
units (cfu)/mL, single colonies with morphological Gram-
negative characteristics were subcultured on MacConkey agar
following standard laboratory procedures guidelines. Isolates
were subjected to species identification using API ID 32 E
(bioMérieux). A total of 44 non-duplicate clinical isolates of
E. coli from 44 patients with UTI were obtained for the study.
Phylogenetic and Multilocus Sequence
Typing
DNA from E. coli isolates were subjected to triplex PCR targeting
the chuA gene, the yjaA gene and an unspecified DNA fragment
termed TspE4.C2, as described previously (Clermont et al.,
2000). Isolates were classified as belonging to one of the four
phylogenetic groups A, B1, B2, or D.
For multilocus sequence typing of E. coli isolates, internal
fragments of the seven housekeeping genes (adk, fumC, gyrB,
icd, mdh, purA, and recA) were amplified by PCR from DNA, as
described by Wirth et al. (2006). Sequencing of the amplification
products was performed by Microsynth (Balgach). Sequences
were imported into the E. coli MLST database website (http://
mlst.warwick.ac.uk/mlst/dbs/Ecoli) to determine MLST types.
Alleles and STs that had not been previously described were
designated new ST, but not assigned numerical designations,
since whole-genome sequencing was not performed.
All ST131 isolates were further analyzed using CH typing
based on fumC and fimH allele combination (Weissman et al.,
2012). Isolates belonging to the ST131-CTX-M-15-H30-Rx
sublineage were identified by detection of the specific amino
acid alteration Gly723→Ala within the allantoin transporter-
encoding gene, ybbW, using PCR primers and conditions
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described previously (Banerjee et al., 2013b). Isolates typed ST10,
ST69, ST73, ST140 (CC95), ST127, and ST131 were regarded as
belonging to major UPEC clones.
Virulence Factor (VF) Determination
All 44 isolates were screened for genetic markers of virulence
associated with ExPEC by conventional PCR using primers and
conditions described previously for afa, papAH, papC, papEF,
sfaS, fyuA, hlyA, iutA, KpsMII, PAI, and traT (Johnson and Stell,
2000; Johnson et al., 2015), vat and yfcV (Spurbeck et al., 2012).
The aggregate VF score was defined as the number of unique VF
detected for each isolate, counting the PAI marker as one.
Strains that were negative for KpsMII were tested by PCR for
the presence of the group 2 capsule subgroup K15 as described by
Johnson et al. (2015).
Isolates that were positive for ≥2 of the five markers afa,
papAH, and/or papC, sfa, KpsM II, or iutA were presumed to be
ExPEC, and isolates that tested positive for ≥3 of the four genes
chuA, fyuA, vat, or yfcV were considered UPEC, as described by
Johnson et al. (2015).
Strains that tested negative for all VFs were screened by PCR
for the presence of aggR, which encodes is a transcriptional
regulator of enteroaggregative E. coli (EAEC) (Boisen et al.,
2012).
Phenotypic and Genotypic Antimicrobial
Resistance Testing
Antimicrobial susceptibility testing was performed using the
disk-diffusion method and the antibiotics ampicillin (AM),
amoxicillin-clavulanic acid (AMC), cefotaxime (CTX), nalidixic
acid (NA), ciprofloxacin (CIP), gentamicin (GM), kanamycin
(K), streptomycin (S), sulfamethoxazole (SMZ), trimethoprim
(TMP) tetracycline (T), and chloramphenicol (C) (Becton
Dickinson, Heidelberg, Germany). Results were interpreted
according to Clinical and Laboratory Standards Institute (CLSI)
performance standards (Clinical Laboratory Standards Institute,
2016). For sulfamethoxazole, for which breakpoints are not listed
separately from trimethoprim, an inhibition zone of ≤10mm
was interpreted as resistant. Isolates displaying resistance to three
or more classes of antimicrobials (counting ß-lactams as one
class) were defined as multidrug-resistant (MDR). Synergistic
effects between AMC and CTX were regarded as an indication
of the presence of an ESBL producer (Kaur et al., 2013). Putative
ESBL producers were grown on BrillianceTM ESBL agar (Oxoid,
Hampshire, UK). The presence of blaESBLs was confirmed by
PCR and amplicons were sequenced as described previously
(Pitout et al., 1998; Woodford et al., 2006; Geser et al., 2012;
Zurfluh et al., 2015). Quinolone-resistant strains were examined
for mutations in quinolone resistance-determining regions
(QRDRs) of gyrA and parC, using previously described PCR
and sequencing primers (Zurfluh et al., 2014). Screening for the
plasmid-mediated fluoroquinolone resistance genes aac(6′)-Ib-
cr, qnrA, qnrB, qnrC, qnrD, qnrS, and qepA genes was carried
out as described previously (Park et al., 2006; Robicsek et al.,
2006; Cattoir et al., 2007; Cavaco et al., 2009; Kim et al., 2009;
Wang et al., 2009; Karczmarczyk et al., 2010; Zurfluh et al., 2014).
Screening for the plasmid-mediated colistin resistance genes
mcr-1, mcr-2 and the plasmid-mediated azithromycin resistance
gene mph(A) was performed using previously published primers
(Ojo et al., 2004; Liassine et al., 2016; Liu et al., 2016) using
appropriate positive controls (Nüesch-Inderbinen et al., 2016;
Zurfluh et al., 2017).
Primers used in this study for targeting virulence and
antimicrobial resistance genes are listed in Supplementary Table
S1. Synthesis of primers and DNA custom sequencing was
carried out by Microsynth (Balgach, Switzerland) and nucleotide
sequences were analyzed with CLC Main Workbench 6.6.1. For
database searches the BLASTN program of NCBI (http://www.
ncbi.nlm.nih.gov/blast/) was used.
Statistical Analysis
Comparisons of proportions of E. coli STs, proportions
of virulence genes and ExPEC/UPEC status within patient
comorbidity status were performed by Fisher’s exact test in a
series of individual pairwise comparisons using 2 × 2 tables
where each characteristic was determined as present or absent.
The significance criterion was set at p ≤ 0.05. Calculations
were performed using the VassarStats website for statistical
computation (http://www.vassarstats.net).
RESULTS
Demographic and Clinical Data
The 44 strains analyzed in this study were isolated from urine
samples of 44 patients with a female/male ratio of 39/5, and
a median age of 53. Ages ranged from 16 to 87 and were
allocated to either group 1, 16–45 years (n = 18), or group
2, 46–87 years (n = 26), respectively (Table 1). A history of
hospitalization during the 4 months before participation in the
study was noted for 2 (4.5%) of the patients (Supplementary
Table S2). None of the patients had a history of antimicrobial
therapy in the 4 months before sample collection. Comorbidities
were recorded for 17 (38.6%) of the patients (five in age group
1 and 12 in age group 2) and are summarized in Table 1
and detailed in Supplementary Table S2. Treatment following
clinical diagnosis of UTI included fosfomycin (19/43.2% of
the patients), norfloxacin (12/27.3%), ciprofloxacin (4/9%), or
sulfamethoxazole/trimethoprim (3/6.8%). Six (13.6%) of the
patients received no treatment (Supplementary Table S2).
Phylogenetic Groups, STs and VF
Distribution
The majority (52.3%) of the 44 UPEC isolates belonged to
phylogenetic group B2, followed by group D (22.7%), group
A (13.6%) and B1 (11.4%). Twenty-seven different ST were
identified, the four most common represented by ST131 (n
= 6/13.6% of the isolates), ST69 (n = 6/13.6%), ST141 (n =
5/11.4%) and ST73 (n = 3/6.8%). Overall, 19 (43.2%) showed
STs associated with major UPEC clonal groups (ST10, ST69,
ST73, ST140, ST127, or ST131). Two (4.5%) belonged to ST12,
and ST14, which are found occasionally among UPEC (Banerjee
et al., 2013a; Nichols et al., 2016). Twenty (45.5%) of the isolates
belonged to STs that occurred only once, whereof three were
new STs. The new STs were not assigned numerical designations
by the E. coli MLST database (http://mlst.warwick.ac.uk/mlst/
dbs/Ecoli), however, the allelic profiles were related to those of
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TABLE 1 | Demographic and clinical features of 44 UPEC belonging to major clonal complexes (CC) and to other sequence types (ST).
Feature Total (n = 44) No. isolates by ST
Major UPEC lineages (n = 19) Other STs (n = 25)
CC10
ST10
(n = 2)
CC69
ST69
(n = 6)
CC73
ST73
(n = 3)
CC95
ST140
(n = 1)
CC131
ST131
(n = 6)
ST127 ST141 Singly occurring
(n = 1) (n = 5) STsa (n = 20)
AGE GROUP
16–45 years 18 1 2 1 0 3 1 2 8
46–87 years 26 1 4 2 1 3 0 3 12
GENDER
Female 39 2 6 1 1 5 1 5 18
Male 5 0 0 2 0 1 0 0 2
COMORBIDITIES
Cancer 4 – – – – – – – 4
CVD 3 – – 1 – 1 – – 1
Diabetes 3 – – – – 1 – 1 1
GID 2 – – – – – – – 2
MS 1 – – – – – – – 1
Polymorbidity 4 – – – 1 1 – – 2
None 27 2 6 2 0 3 1 4 9
aSingly occurring STs included ST12 (n = 1), ST14 (n = 1); ST1193 (n = 1); ST59 (n = 1), ST349, (n = 1), ST108 (n = 1), ST841 (n = 1), ST58 (n = 1), ST4628 (n = 1), ST2628 (n = 1),
ST1851 (n = 1), ST40 (n = 1), ST720 (n = 1), ST681(n = 1), ST978 (n = 1), ST1001 (n = 1), ST4299 (n = 1), new STs (n = 3). The ST were not assigned numerical designations by
the E. coli MLST database (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli). CVD, cardiovascular diseases; GID, gastrointestinal diseases (irritable bowel syndrome and sigmoid diverticulitis,
respectively); MS, multiple sclerosis; –, not observed.
ST23 (n = 2) and ST165 (n = 1) (Supplementary Table S3).
Subtyping of the ST131 isolates identified five isolates with the
fumC/fimH type 40-30, and one isolate with the fumC/fimH
type 40–41 (Supplementary Table S2). Accordingly, the isolates
were assigned to the subclones ST131-H30 and ST131-H41,
respectively. All five ST131-H30 isolates were fluoroquinolone
resistant and thus considered to belong to the subclone H30-R
as determined by Price et al. (2013). Furthermore, both ST131-
CTX-M-15 isolates were identified as belonging to the H30-Rx
sublineage (Price et al., 2013).
The distribution of STs among the age groups, genders and
comorbidities of the patients is shown in Table 1. ST distribution
was invariable for age groups and gender, but varied by health
status. The majority (n = 14/73.7%) of the 19 isolates that
belonged to major UPEC lineages were isolated from patients
without comorbidities, without reaching statistical significance
(p = 0.2133). By contrast, the majority (n = 11/64.7%) of the 20
isolates that belonged to singly occurring STs were from patients
for whom comorbidities were noted, approximating, but not
reaching statistical significance (p= 0.0633).
Overall, 90.9% of the isolates tested positive for one or more
of the VF genes (Table 2). Among the 44 isolates, the prevalence
of individual VF genes ranged from 13.6% (afa) to 70.5% (fyuA).
None of the KpsMII negative isolates were positive for K15 (data
not shown). The overall median aggregate VF scores (and ranges)
were lowest for isolates belonging to ST10 (median VF score 3.5,
range 3–4) and highest for ST127 (median VF score 9, range
9) and ST141 (median VF score 11, range 5–12). Among the
different STs, PAI, yfcv and hlyA were distinguished by their
absence from ST69 (Table 2).
Applying the criteria for ExPEC and UPEC described above,
27 (61.4%) of the isolates qualified as ExPEC, and 22 (50%) as
UPEC (Supplementary Table 2).
No statistically significant associations were observed for
STs, VFs, or ExPEC/UPEC status with comorbidities (data not
shown).
Notably, four (9%) of the isolates (belonging to a new
ST, to ST40, ST841, and ST1001, respectively), tested negative
for all ExPEC VF (Supplementary Table S2). Screening of
these isolates for aggR remained negative throughout (data not
shown).
Antimicrobial Susceptibility
Antimicrobial susceptibility rates for the E. coli isolates are
summarized in Table 2 and shown in detail in Supplementary
Table S2. Overall, 22 (50%) of the isolates remained susceptible
to all antimicrobials tested. None of the isolates were resistant
to fosfomycin or to nitrofurantoin. Isolates belonging to ST131
were the most extensively resistant, exhibiting a high prevalence
of 83.3% of MDR, ciprofloxacin resistance, and ampicillin
resistance. ST69 was characterized by a prevalence of 66.7% of
MDR, trimethoprim and ampicillin resistance as well as a high
rate of 83.3% resistance to sulfamethoxazole (Table 2). Overall,
10 (22.7%) of the isolates were resistant to nalidixic acid, and
seven thereof were ciprofloxacin resistant (Table 2). Among
the isolates displaying ciprofloxacin resistance, all revealed
chromosomal mutations leading to amino acid substitutions in
GyrA and ParC (Table 3). Only one of the ciprofloxacin resistant
ST131 strains harbored the aac(6′)-Ib-cr gene. Further, one
(16.7% of all E. coli ST69) and three (50%) of the ST131 isolates
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TABLE 2 | Genotypic and phenotypic characteristics of 44 UPEC belonging to major clonal complexes (CC) or to other sequence types (ST).
Feature No. (%) of isolates by ST
Major UPEC clones Other STs
CC10
ST10
(n = 2)
CC69
ST69
(n = 6)
CC73
ST73
(n = 3)
CC95
ST140
(n = 1)
ST127
(n = 1)
CC131
ST131
(n = 6)
ST141
(n = 5)
Singly occurring
STsa (n = 20)
Total (%)
VF GENES
afa 1 (50) 1 (16.7) 0 (0) 0 (0) 0 (0) 4 (66.7) 0 (0) 0 (0) 6 (13.6)
papAH 0 (0) 3 (50) 1 (33.3) 0 (0) 1 (100) 2 (33.3) 3 (60) 6 (30) 16 (36.4)
papC 0 (0) 3 (50) 1 (33.3) 0 (0) 0 (0) 2 (33.3) 3 (60) 6 (30) 15 (34)
papEF 0 (0) 4 (66.7) 1 (33.3) 0 (0) 1 (100) 2 (33.3) 3 (60) 5 (25) 16 (36.4)
sfaS 0 (0) 0 (0) 3 (100) 0 (0) 1 (100) 0 (0) 5 (100) 4 (20) 13 (29.5)
yfcv 1 (50) 0 (0) 3 (100) 1 (100) 1 (100) 4 (66.7) 5 (100) 8 (40) 23 (52.3)
hlyA 0 (0) 0 (0) 3 (100) 0 (0) 1 (100) 1 (16.6) 3 (60) 4 (20) 12 (27.3)
vat 0 (0) 0 (0) 3 (100) 1 (100) 1 (100) 0 (0) 4 (80) 6 (30) 15 (34)
fyuA 1 (50) 4 (66.7) 3 (100) 1 (100) 1 (100) 6 (100) 5 (100) 10 (50) 31 (70.5)
iutA 2 (100) 5 (83.3) 0 (0) 1 (100) 0 (0) 5 (83.3) 4 (80) 7 (35) 24 (54.5)
KpsMII 1 (50) 5 (83.3) 3 (100) 1 (100) 1 (100) 5 (83.3) 4 (80) 10 (50) 30 (68.2)
PAI 0 (0) 0 (0) 3 (100) 1 (100) 1 (100) 4 (66.7) 5 (100) 8 (40) 22 (50)
traT 1 (50) 5 (83.3) 0 (0) 0 (0) 0 (0) 4 (66.7) 2 (40) 8 (40) 20 (45.5)
VF score [mean, median, (range)] 3.5,3.5, (3–4) 5, 5, (2-7) 8, 7 (7–10) 6, 6, (6) 9, 9, (9) 6.5, 7, (5–7) 9.2, 11,(5–12) 4.1, 3.5 (0–11) 5.5, 5.5 (0–12)
AMR PHENOTYPEb
Pansusceptible 2 (100) 1 (16.6) 3 (100) 1 (100) 0 (0) 0 (0) 2 (40) 13 (65) 22 (50)
Fosfomycin 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Nitrofurantoin 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Ciprofloxacin 0 (0) 1 (16.6) 0 (0) 0 (0) 0 (0) 5 (83.3) 0 (0) 1 (5) 7 (15.9)
Sulfamethoxazole 0 (0) 5 (83.3) 0 (0) 0 (0) 0 (0) 4 (66.7) 1 (20) 4 (20) 14 (31.8)
Trimethoprim 0 (0) 4 (66.7) 0 (0) 0 (0) 0 (0) 3 (50) 0 (0) 2 (10) 9 (20.5)
Ampicillin 0 (0) 4 (66.7) 0 (0) 0 (0) 0 (0) 5 (83.3) 2 (40) 3 (15) 14 (31.8)
Cefotaxime 0 (0) 1 (16.6) 0 (0) 0 (0) 0 (0) 3 (50) 0 (0) 0 (0) 4 (9)
MDR 0 (0) 4 (66.7) 0 (0) 0 (0) 0 (0) 5 (83.3) 2 (40) 2 (10) 13 (29.5)
ACQUIRED AMR GENESc
aac(6′)-Ib-cr 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.6) 0 (0) 0 (0) 1 (2.3)
blaCTX−M−14 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.6) 0 (0) 0 (0) 1 (2.3)
blaCTX−M−15 0 (0) 1 (16.6) 0 (0) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0) 3 (6.8)
mph(A) 0 (0) 4 (66.7) 0 (0) 0 (0) 0 (0) 2 (33.3) 0 (0) 0 (0) 6 (13.6)
aSingly occurring ST included ST12 (n = 1), ST14 (n = 1); ST1193 (n = 1); ST59 (n = 1), ST349, (n = 1), ST108 (n = 1), ST841 (n = 1), ST58 (n = 1), ST4628 (n = 1), ST2628 (n = 1),
ST1851 (n = 1), ST40 (n = 1), ST720 (n = 1), ST681 (n = 1), ST978 (n = 1), ST1001 (n = 1), ST4299 (n = 1), new ST (n = 3). The new STs were not assigned numerical designations
by the E. coli MLST database (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli).
bThe most important antimicrobials for UTI treatment, as well as ß-lactams are shown. A detailed overview of all resistance profiles is given in Supplementary Table S2.
AMR, antimicrobial resistance; CC, clonal complex; MDR, multidrug resistance; ST, sequence type; UPEC, uropathogenic E. coli; VF, virulence factor.
cNone of the isolates harbored the plasmid-mediated colistin resistance genes mcr-1 or mcr-2.
were ESBL producers and resistant to cefotaxime. These ESBLs
were CTX-M-14 (n = 1) and CTX-M-15 (n = 3) (Table 2). Of
note was the association of the plasmid-mediated azithromycin
resistance genemph(A) with ST69 and ST131.
DISCUSSION
In this study, we characterized the clonal diversity, virulence
potential and antimicrobial resistance characteristics of
UPEC obtained from unselected patients attending a general
practitioner between February and October 2016 in Switzerland.
Such isolates are not usually available, since the current
practice of treatment does not involve obtaining a urine
specimen for culture, except in the case of more severe
infection.
The UPEC population was characterized by a diversity of
clonal lineages and sequence types. Although major UPEC
lineages ST10, ST69, ST73, ST140 (belonging to CC95), ST127
and ST131 were detected in 43.2% of the cases, our results show
that the majority (56.8%) of E. coli causing UTI in primary care
patients in this particular setting belongs to other STs, irrespective
of the patients’ health status.
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TABLE 3 | Amino acid substitutions in the QRDR of ciprofloxacin resistant UPEC
isolates.
QRDR
gyrA parC
E. coli ST (n) Ser83→ Leu Asp87→ Asn Ser80→ Ile Glu84→ Val
(%) (%) (%) (%)
69 (1) 1 (100) 1 (100) 1 (100) 0 (0)
131 (5) 5 (100) 5 (100) 5 (100) 5 (100)
1193 (1) 1 (100) 1 (100) 1 (100) 0 (0)
Asn, asparagine; Asp, aspartic acid; Glu, glutamic acid; gyrA: DNA gyrase (type
II topoisomerase) gene; Ile, isoleucine; Leu, leucine; parC, topoisomerase IV gene;
QRDR, quinolone resistance determining region; Ser, serine; ST, sequence type; UPEC,
uropathogenic E. coli; Val, valine.
Among the major UPEC lineages, we observed ST131 isolates
belongingto twodifferentsubclones,H30-RandH41, respectively.
Further, we detected non-ESBL and ESBL-producers among
the ST131-H30-R strains, including CTX-M-14 and CTX-M-15
producing strains. The prevalence of E. coli ST131-CTX-M-15-
H30-Rx among primary care UPEC isolates in this study was
4.5%. Currently, available studies with which to compare our
results are scarce. In a previous study on clinical ESBL producing
E. coli isolates in Switzerland, Seiffert et al. (2013) observed
fluoroquinolone resistant CTX-M-15 producing E. coli ST131 in
two of 95 (2.1%) community-associated UTI. However, lack of
data on the clonal background of these earlier strains limits a
direct comparison and highlights the need of further studies to
assess the prevalence of ST131-H30-Rx among UPEC isolates in
Switzerland.Ourfindingssuggest thatmultiple subclonesofST131
are circulating in the community, likely as intestinal commensals,
as suggested previously (Leflon-Guibout et al., 2008). Moreover,
this study shows that E. coli ST131 and ST69 are disseminators of
the plasmid-mediated azithromycin resistance gene mph(A) and
that this gene occurs in isolates in the absence of any apparent
selective pressure such as history of antimicrobial therapy or
hospitalization of the patient. The dissemination of resistance to
macrolides representsa threat to the treatmentof infectionscaused
by Salmonella and Shigella spp. and warrants further attention
(Phuc Nguyen et al., 2009; Baker et al., 2015).
Interestingly, only one (2.1%) of the isolates (ST140) in this
study belonged to CC95. This is similar to previous observations
for community and hospital derived UPEC isolates from the
United Kingdom and from Germany (Croxall et al., 2011; Toval
et al., 2014). By contrast, this clone is more prevalent among
UTI in the U.S.A. and Australia (Banerjee et al., 2013a; Gordon
et al., 2017). Therefore, although CC95 strains occur globally,
their distribution is unequal across continents and countries.
Our findings suggest that the uncomplicated CAUTI may not
commonly caused E. coli CC95 in this particular geographical
setting.
Some other STs identified in this study are infrequently
associated with UPEC, including ST10, ST12, and ST14,
(Banerjee et al., 2013a; Nichols et al., 2016), and ST141 (Toval
et al., 2014; Leatham-Jensen et al., 2016). ST141 has also been
identified in the fecal flora of healthy individuals (Leflon-
Guibout et al., 2008). The results from this study suggest that
ST141 has emerged as a UPEC clone in the community in
Switzerland.
A substantial percentage (38.6 and 50%, respectively) of the
isolates did not meet the ExPEC or UPEC criteria defined for
this study. Moreover, four (9%) of the isolates did not reveal
any ExPEC or UPEC associated VF and in addition remained
susceptible to all antimicrobials tested. Since UTI is sporadically
caused by EAEC (Herzog et al., 2014; Lara et al., 2017), these
four isolates were screened for the EAEC marker gene aggR.
However, all remained negative and the virulence mechanisms
of these UPEC isolates remain to be further characterized. These
observations are supportive of a concept involving a broader
definition of the ability of E. coli to cause uncomplicated CAUTI
in humans with or without comorbidities, such as bacterial
transcriptional regulation and host susceptibility (Schreiber et al.,
2017). Nonetheless, although the panel of VFs examined included
acknowledged UPEC associated genes, it is limited in number
and is composed of only a subset of known VFs. Other important
determinants of UPEC may have been overlooked, including
minor sequence variants of known VFs and unrecognized
VFs. Further limitations of this study is the small sample size
which could have compromised statistical power, consequently
introducing the possibility of type II errors, i.e., failure to detect
a difference when one actually exists. Finally, this study was
conducted with samples originating from one particular practice
for general medicine in a single suburban setting. Caution
should be exercised in making generalizations across different
populations, countries and settings.
Treatment for UTI at community level in Switzerland
as in other countries, is for the most part empirical and
follows the recommendations of the Infectious Diseases
Society of America (IDSA) and the European Society
for Microbiology and Infectious Diseases (ESCMID)
(Gupta et al., 2011). Recommendations include fosfomycin,
sulfamethoxazole/trimethoprim (SMZ/TMP), nitrofurantoin,
and pevmecillinam, with fluoroquinolones approved as an
important alternative agent. A resistance prevalence of 20%
is considered the threshold at which an antimicrobial is no
longer recommended. In this study, 31.8% of the UPEC isolates
were resistant to SMZ, and 15.9% to CIP. Therefore, the use of
SMZ/TMP for the empirical treatment of UTI due to UPEC at
primary care level in this region is questionable, and the safety
of treatment with fluoroquinolones is threatened. By contrast,
fosfomycin remains a valuable antimicrobial for treating CAUTI
due to E. coli, including infections caused by pandemic, highly
virulent MDR UPEC clones.
In conclusion, we found that UTI in primary care patients in
the study community in Switzerland is caused by a diversity of E.
coli STs, including, but not predominantly, pandemic clones such
as ST131, ST69. E. coli ST141 was identified as an emerging clone
that is associated withUTI in the community, andwarrants closer
attention. Antimicrobial resistance and carriage of plasmid-
mediated blaCTX−M and mph(A) is linked to ST131 including
its globally disseminated sublineage H30-Rx, and ST69. Our
results indicate that SMZ/TMP and fluoroquinolone resistance
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in UPEC in the primary care setting may compromise the
treatment of UTI. By contrast, fosfomycin remains an optimal
first line antimicrobial for the treatment of UTI at primary care
level.
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